| Induction chemotherapy in patients with locally-advanced head and neck squamous cell carcinoma: docetaxel and cisplatin |
|
Young Jin Choi, Ho Jin Shin, Joo Seop Chung, Goon Jae Cho, Byung Joo Lee, Soo Geon Wang |
|
Cardiology Division, Department of Internal Medicine, Yeungnam University Hospital1 |
| 원저 : 국소 진행성 두경부암 환자에서 docetaxel과 cisplatin을 이용한 유도 화학요법 |
|
최영진.신호진.정주섭.조군제.이병주.왕수건, Ho Jin Shin, Joo Seop Chung, Goon Jae Cho, Byung Joo Lee, Soo Geon Wang |
|
|
|
|
|
|
| Abstract |
|
Background : This prospective study was conducted to assess the efficacy and toxicity of induction chemotherapy
with docetaxel and cisplatin for patients with previously untreated, locally advanced squamous cell carcinoma of the head
and neck (SCCHN).
Methods : Forty four patients received 120 courses of treatment with docetaxel (70 mg/m2 in a 1-hour infusion) and
cisplatin (75 mg/m2 in a 1-hour infusion), repeated every 3 weeks. Responsive patients (complete response: CR, or partial
response: PR) received one more course of chemotherapy before undergoing local radiotherapy.
Results : All 44 patients were assessable for response and toxicity analysis. The most common grade 3/4 adverse
events were neutropenia, which occurred in 23 patients. Four cases of febrile neutropenia were noted. The overall
response rate was 90% (CR 45% & PR 45%). The four year probability of time to treatment failure was 56.3¡¾10.2%.
The four year estimated overall survival rates were 87.4¡¾6.9%.
Conclusions : Docetaxel and cisplatin induction chemotherapy shows considerable CR, with an acceptable toxicity
profile in patients with locally advanced head and neck squamous cell carcinoma.(Korean J Med 73:415-422, 2007) |
| Key Words:
Docetaxel, Cisplatin, Head and neck cancer, Induction chemotherapy |
|
PDF Links
Full text via DOI
Download Citation
